These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 8697306

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ, Castillo MJ, Lefèbvre PJ.
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [Abstract] [Full Text] [Related]

  • 31. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
    Faber OK, Binder C.
    Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
    [Abstract] [Full Text] [Related]

  • 32. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J, Barrow BA, Levy JC, Turner RC.
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [Abstract] [Full Text] [Related]

  • 33. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation.
    Mari A, Tura A, Gastaldelli A, Ferrannini E.
    Diabetes; 2002 Feb; 51 Suppl 1():S221-6. PubMed ID: 11815483
    [Abstract] [Full Text] [Related]

  • 34. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
    Montgomery TM, Nelson RW, Feldman EC, Robertson K, Polonsky KS.
    J Vet Intern Med; 1996 Feb; 10(3):116-22. PubMed ID: 8743209
    [Abstract] [Full Text] [Related]

  • 35. A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
    Scionti L, Misericordia P, Santucci A, Santeusanio F, Brunetti P.
    Acta Diabetol; 1992 Feb; 29(1):20-4. PubMed ID: 1520901
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.